Tb
Just to make sure I focus on what you need - tuberculosis is a broad topic. What would you like to know?
Asking for Preferences
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Searching PubMed
tuberculosis treatment regimen
Searching the Web
tuberculosis treatment regimen guidelines 2026
Good - this confirms and updates the textbook info with a 2025 consolidated ATS/CDC/ERS/IDSA guideline update. Here's a complete answer on TB treatment.
Tuberculosis (TB) Treatment / Drug Regimens
1. Active, Drug-Susceptible TB
Standard 6-month regimen (traditional, still widely used):
- Intensive phase (2 months): Isoniazid (INH) + Rifampin (RIF) + Pyrazinamide + Ethambutol, daily
- Continuation phase (4 months): Isoniazid + Rifampin
Newer 4-month regimen (2021 Study 31/A5349, now incorporated into 2025 ATS/CDC/ERS/IDSA consolidated guidelines, for age ≥12 with non-severe disease):
- Isoniazid + Rifapentine + Pyrazinamide + Moxifloxacin for 2 months, then Isoniazid + Rifapentine + Moxifloxacin for 2 more months
Isoniazid and rifampin are the most active drugs in the combination; pyrazinamide added during the intensive phase allows the overall duration to be shortened. Ethambutol is included mainly as protection until drug susceptibility is confirmed - it doesn't add efficacy in susceptible isolates and can be dropped once isoniazid/rifampin susceptibility is known (Katzung's Basic and Clinical Pharmacology, p. 1312).
Alternative CDC-approved dosing schedules (Tintinalli's Emergency Medicine, p. 496):
- Daily 4-drug x8 weeks -> INH/RIF or INH/rifapentine x18 weeks
- Daily 4-drug x2 weeks, then twice-weekly x6 weeks -> INH/RIF or INH/rifapentine x18 weeks
- Three-times-weekly 4-drug x8 weeks -> INH/RIF three-times-weekly x18 weeks
- Daily 3-drug (INH, RIF, ethambutol) x8 weeks -> INH/RIF x31 weeks (if pyrazinamide can't be used)
Prolong therapy for immunocompromised patients, cavitary disease with a positive culture after 2 months, or extrapulmonary disease (CNS, skeletal, disseminated).
2. Drug-Resistant TB
- Isoniazid-resistant, rifampin-susceptible: Rifampin + Ethambutol + Pyrazinamide + Levofloxacin for 6 months (Harrison's Principles of Internal Medicine, 22nd ed.)
- Rifampin-resistant / MDR-TB (age ≥14): All-oral 6-month regimen of Bedaquiline + Pretomanid + Linezolid (BPaL), with moxifloxacin added if fluoroquinolone-susceptible (BPaLM). This has replaced the older 18-24 month multi-drug injectable-containing regimens. Management should be guided by susceptibility testing and ideally an infectious disease/TB expert.
3. Latent TB Infection (LTBI)
- Isoniazid alone for a minimum of 9 months (for recent skin-test conversion, close contacts of active cases, anergic patients with known exposure) - reduces progression risk by roughly 70%
- Rifampin + Pyrazinamide x2 months if exposed to INH-resistant strains or INH-intolerant (needs hepatotoxicity monitoring)
- Rifapentine + Isoniazid (shorter, e.g. 12-week once-weekly regimen) for patients unlikely to complete 9 months (Tintinalli's Emergency Medicine, p. 497-498)
Key Toxicities to Monitor
| Drug | Main Adverse Effect |
|---|---|
| Isoniazid | Hepatotoxicity (5-33% mild transaminase elevation); peripheral neuropathy (give pyridoxine/B6) |
| Rifampin | Hepatotoxicity, drug interactions (CYP450 inducer), orange body fluids |
| Pyrazinamide | Hepatotoxicity, hyperuricemia/gout |
| Ethambutol | Optic neuritis/visual disturbance (reversible if stopped promptly) |
| Bedaquiline | QT prolongation |
| Linezolid | Myelosuppression, peripheral/optic neuropathy (long-term use) |
Stop anti-TB therapy if AST/ALT >5x upper limit of normal or bilirubin >3 mg/dL (Tintinalli's Emergency Medicine, p. 496).
Recent Evidence Update
2025 network meta-analyses support these newer approaches:
- All-oral bedaquiline-based shorter regimens show improved outcomes for drug-resistant TB (PMID: 40194835)
- High-dose rifamycin regimens are being compared for potential to further shorten treatment (PMID: 41047272)
- Shorter MDR/RR-TB regimens continue to show comparable efficacy/safety versus older long regimens (PMID: 39354416)
These findings align with the 2025 ATS/CDC/ERS/IDSA consolidated guidelines that now favor the 4-month regimen for drug-susceptible TB and 6-month all-oral BPaL/BPaLM for drug-resistant TB over historically longer regimens.
Note: Actual initiation and regimen selection should always be individualized based on drug-susceptibility testing, HIV status, pregnancy, and local public health protocols (TB is a reportable disease). This is educational information, not a substitute for clinical guidance from a treating physician or public health TB program.
Dosage
Reading File
Reading File
Here are the standard dosages for TB medications, drawn from Katzung's Basic and Clinical Pharmacology and Tintinalli's Emergency Medicine.
First-Line Anti-TB Drug Dosages (Adults)
| Drug | Daily Dose (max) | 3x/week DOT (max) | 2x/week DOT (max) |
|---|---|---|---|
| Isoniazid (INH) | 5 mg/kg PO (300 mg) | 15 mg/kg (900 mg) | 15 mg/kg (900 mg) |
| Rifampin (RIF) | 10 mg/kg PO (600 mg) | 10 mg/kg (600 mg) | 10 mg/kg (600 mg) |
| Rifapentine | Not given daily | Not given 3x/week | 600 mg twice weekly (adults only; not approved <12 y) |
| Rifabutin | 5 mg/kg PO (300 mg) | 5 mg/kg (300 mg) | 5 mg/kg (300 mg) |
| Ethambutol | 15-25 mg/kg PO (1.6 g) | 25-30 mg/kg (2.5 g) | 50 mg/kg (2.5 g) |
| Pyrazinamide | 15-30 mg/kg PO (2 g) | 50 mg/kg (3 g) | 50 mg/kg (2 g) |
| Moxifloxacin (4-month regimen) | 400 mg/day | - | - |
(Tintinalli's Emergency Medicine, p. 496; Katzung's Basic and Clinical Pharmacology, p. 1312)
Simplified once-daily adult dosing (Katzung's):
- Isoniazid: 300 mg/day
- Rifampin: 600 mg/day
- Pyrazinamide: 25 mg/kg/day
- Ethambutol: 15-25 mg/kg/day
- Rifapentine: 1200 mg once daily (in the 4-month RPT-based regimen)
Second-Line Drug Dosages (for drug-resistant TB)
| Drug | Typical Adult Dosage |
|---|---|
| Amikacin | 15 mg/kg/day |
| Streptomycin | 15 mg/kg/day |
| Capreomycin | 15 mg/kg/day |
| Aminosalicylic acid | 8-12 g/day |
| Bedaquiline | 400 mg/day (loading), then reduced maintenance dosing per protocol |
| Clofazimine | 200 mg/day |
| Cycloserine | 500-1000 mg/day, divided |
| Ethionamide | 500-750 mg/day |
| Levofloxacin | 500-750 mg/day |
| Linezolid | 600 mg/day |
| Pretomanid | 200 mg/day |
(Katzung's Basic and Clinical Pharmacology, p. 1313)
Practical Notes
- Weight-based dosing is preferred for isoniazid, rifampin, pyrazinamide, and ethambutol; the fixed mg amounts above are the usual maximums.
- Pyridoxine (vitamin B6), 25-50 mg/day, should be co-administered with isoniazid to prevent peripheral neuropathy, especially in patients who are pregnant, malnourished, diabetic, have HIV, or have renal failure.
- Pediatric dosing differs and is weight-based - the CDC (cdc.gov/tb) is cited as the reference for accurate pediatric weight-based protocols.
- Intermittent (3x or 2x weekly) dosing must be given as directly observed therapy (DOT).
- Rifapentine is not recommended for HIV-positive patients on the intermittent continuation regimen per CDC guidance (increased relapse risk with rifamycin resistance).
- Renal or hepatic impairment requires dose adjustment (e.g., ethambutol and aminoglycosides are renally cleared and need adjustment in renal insufficiency).
These are general adult reference dosages - actual prescribing must be individualized based on body weight, renal/hepatic function, drug susceptibility results, and local TB program protocols.
This is a shared conversation. Sign in to Orris to start your own chat.